The association between the CHEK2 gene and breast cancer risk has been supported mainly by case-control studies of founder mutations such as 1100delC, I157T (frequent in northern and eastern Europe) or the Polish founder mutation IVS2+1 G > A (c.444+1G > A) [19,20,24,43,44]. This evidence concerns the gene CHEK2 and breast carcinoma.